UNSPSC 51332101: Dobupride

This classification denotes an antipsychotic agent with the molecular formula C20H30ClN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FW0Z2U7O23, chemically known as 4-amino-2-butoxy-5-chloro-n-(1-(1,3-dioxolan-2-ylmethyl)-4-piperidyl)benzamide but generally known as dobupride, which bears US NIH Compound Identifier 65896. European Medicines Agency schedules Dobupride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06342MIG.

UNSPSC 51332101 Dobupride is a Commodity code that does not align with the recent state and local procurement activity tagged under it. The source shows three recent opportunities posted under this code, but none involve dobupride—a cardiac agent used in human pharmaceutical treatment. Instead, the tagged solicitations cover naloxone procurement, therapeutic pharmacy initiatives, and generic multi-source pharmaceutical distribution, none of which relate to dobupride. The mismatch suggests that this code either sees minimal relevant recent activity or has been incorrectly applied to these opportunities by the issuing bodies.

The recent opportunities do reveal broader pharmaceutical and health-product procurement activity across state and local jurisdictions. Seminole County, Florida posted an IFB on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with delivery to its Community Health Building; the Texas Health and Human Services Commission issued an RFI on April 3, 2026, to explore direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP on January 20, 2026, for generic multi-source pharmaceuticals and over-the-counter products across participating state and local facilities, with proposals due March 26, 2026. These opportunities span county health departments, state HHS agencies, and cooperative purchasing vehicles, but they do not track to dobupride specifically. The code shows little decision-relevant activity for vendors focused on dobupride supply or distribution to state and local buyers.